Kyle Woodley

Kyle Woodley

Senior Investing Editor, Kiplinger

Kyle Woodley is the Senior Investing Editor of Kiplinger.com. His articles covering stock picks, exchange-traded funds and mutual funds have been featured on MSN, Nasdaq and U.S. News & World Report. He also has appeared on Fox Business Network.

He previously was Managing Editor of InvestorPlace.com, and an award-winning designer and copy editor with Gannett. He also is a graduate of Ohio State University.

Kyle can be reached at kwoodley@kiplinger.com, or you can follow him on Twitter at @KyleWoodley.

Recent Articles

50 Blue-Chip Stocks Increasing Dividends in Q1 2013

By Kyle Woodley, Senior Investing Editor, Kiplinger

What's not to love about a big, blue-chip stock that has put its money where its shareholders are with even bigger payouts? These 50 companies did just that in the first quarter of 2013.

Biotech Movers: Peregrine, PharmAthene Climb on Analyst Coverage

By Kyle Woodley, Senior Investing Editor, Kiplinger

Last week in biotech news, Peregrine and PharmAthene both climbed on bullish analyst coverage. Also, find out why Sequenom shed double-digits in one day.

Don’t Dismiss the Ol’ Diamonds

By Kyle Woodley, Senior Investing Editor, Kiplinger

Don't let your financial savvy blind you to the potential for big gains from the DIA exchange-traded fund.

Biotech Movers: Affymax Crashes on Recall

By Kyle Woodley, Senior Investing Editor, Kiplinger

Last week, shares of Affymax got hammered when the company pulled back units of its sole commercial drug. Plus, find out what sent the biggest gainers skyward.

Joe’s Jeans; Or, Why I Love Making Mistakes

By Kyle Woodley, Senior Investing Editor, Kiplinger

Everyone screws up sometimes. The least you can do is learn from the experience.

Biotech Movers: Chelsea Doubles, Vivus Dips

By Kyle Woodley, Senior Investing Editor, Kiplinger

Last week, Vivus slipped on a rejection from European regulators. Plus, find out why Chelsea Therapeutics and Infinity Pharmaceuticals soared.

Biotech Movers: Big Bumps All Around

By Kyle Woodley, Senior Investing Editor, Kiplinger

Last week, big names from Ziopharm Oncology to StemCells posted stellar gains, while Amicus Therapeutics shaked the positive trend with a hearty tumble.

Still Wild for BWLD

By Kyle Woodley, Senior Investing Editor, Kiplinger

Sure, the company faces headwinds -- uncertainty about the minimum wage and higher input costs among them -- but Buffalo Wild Wings has carved out a dedicated niche that's unlikely to fade anytime soon.

Top 10 Dow Dividend Stocks for February

By Kyle Woodley, Senior Investing Editor, Kiplinger

Income investors could do a lot worse than buying into these venerable blue chips -- especially the stock that continues to hold the crown.

Biotech Movers: A Doubler for Opexa

By Kyle Woodley, Senior Investing Editor, Kiplinger

A good week for little guys Opexa Therapeutics and Hyperion Therapeutics and giant Biogen. But Hemispherx BioPharma and BioCryst Pharmaceuticals had downers.

Load More